- Previous Close
1.9300 - Open
1.9300 - Bid 1.5400 x 40000
- Ask 1.9500 x 40000
- Day's Range
1.9300 - 1.9300 - 52 Week Range
0.8890 - 2.3500 - Volume
15 - Avg. Volume
63 - Market Cap (intraday)
68.148M - Beta (5Y Monthly) 0.60
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2700 - Earnings Date Feb 6, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 for emergency treatment of allergic reactions; and OX-MPI for the treatment of endometriosis. In addition, its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
www.orexo.com113
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: ORXOY
View MorePerformance Overview: ORXOY
Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ORXOY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ORXOY
View MoreValuation Measures
Market Cap
57.97M
Enterprise Value
101.04M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.27
Price/Book (mrq)
21.90
Enterprise Value/Revenue
1.89
Enterprise Value/EBITDA
26.07
Financial Highlights
Profitability and Income Statement
Profit Margin
-17.68%
Return on Assets (ttm)
1.12%
Return on Equity (ttm)
-325.00%
Revenue (ttm)
595.7M
Net Income Avi to Common (ttm)
-105.3M
Diluted EPS (ttm)
-0.2700
Balance Sheet and Cash Flow
Total Cash (mrq)
114.9M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
47.48M